Kalaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing treatments for retinal diseases.
KLRS | US
Overview
Corporate Details
- ISIN(s):
- US0198181036
- LEI:
- Country:
- United States of America
- Address:
- 628 MIDDLEFIELD ROAD, 94301 PALO ALTO
- Website:
- https://kalaristx.com/
- Sector:
- Manufacturing
Description
Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for prevalent retinal diseases. The company's lead product candidate, TH103, is a fully humanized, recombinant fusion protein designed for intravitreal delivery. Engineered to be a best-in-class anti-VEGF agent, TH103 acts as a soluble decoy receptor against Vascular Endothelial Growth Factor (VEGF). It possesses a high affinity for both VEGF and heparan sulfate proteoglycans (HSPG), which are believed to act as molecular anchors. This mechanism is designed to extend the therapy's intraocular retention, potentially reducing the frequency of injections for patients. The discovery of TH103 was led by scientific co-founder Dr. Napoleone Ferrara, a key scientist in the development of prior leading anti-VEGF drugs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Kalaris Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Kalaris Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Kalaris Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
